Mr. Arun Menawat reports

PROFOUND MEDICAL ACHIEVES RECORD PRELIMINARY UNAUDITED REVENUE FOR THE 2025 THIRD QUARTER

Profound Medical Corp. has released preliminary unaudited revenue figures for the third quarter of 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars.

For the quarter ended Sept. 30, 2025, Profound anticipates total revenues to be in the approximate range of $5.2-million to $5.3-million, representing revenue growth of between 84 per cent and 87 per cent over $2.8-million in the same three-month period a year ago. Gross margin is expected to be approximately 72 per cent for the third quarter of 2025, compared with 64 per cent in the prior-year period.

"During the third quarter, we achieved new highs in terms of both Tulsa-Pro installed base growth and existing system utilization, driving record total revenues," commented Arun Menawat, Profound's chief executive officer and chairman. "Our Tulsa-Pro installed base now sits at 67 -- up from 60 -- and, due to our strong and growing capital sales pipeline, we continue to expect to reach at least 75 by the end of the year."

These figures are preliminary and unaudited, and actual revenues may differ. The company plans to announce its full third quarter 2025 financial results after market close on Thursday, Nov. 13, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Third quarter 2025 results conference call details

Date:  Thursday, Nov. 13, 2025

Time:  4:30 p.m. ET

Please register for the live call.

The call will also be broadcast live and archived on the company's website under news and events in the investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, artificial-intelligence-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa Procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum, ranging from low-, intermediate- or high-risk prostate cancer to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia, to men with BPH only and also to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The Tulsa Procedure employs real-time MR guidance for precision to preserve patients' urinary continence and sexual function while killing the targeted prostate tissue through precise sound absorption technology that gently heats it to 55 to 57 C. The Tulsa Procedure is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with the Tulsa Procedure. There is no bleeding associated with the procedure, no hospital stay is required and most Tulsa patients report quick recovery to their normal routine. Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.